Top Stories
The CRISPR company raised $128.7 million in its upsized IPO.
The company has submitted a data package to the FDA in support of leaving the rare-disease drug on shelves.
The pharma signed seven licensing agreements to ensure the supply of alimatravir in 129 countries that account for a "substantial majority" of new HIV diagnoses around the world.
Trodelvy plus Keytruda secured a first-line nod in metastatic triple-negative breast cancer, while a regimen consisting of Enhertu plus Perjeta is recommended as a first-line treatment for HER2-positive metastatic breast cancer.
The Danish drugmaker is arguing that Lilly's ads use "outdated" information to create the impression that its obesity and diabetes drugs are superior.
Conference News
Poster presentation builds on Phase 1b PP353 data published in The Lancet's eClinicalMedicine, reinforcing the rationale for a targeted, non-opioid approach to chronic Low Back Pain with Modic changes...
SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases,...
The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessmen...
FirstWord spoke with Mount Sinai's Ranjan Duara about detailed Phase II CELIA data for diranersen from Biogen and Ionis, and what they suggest about it and other tau-targeting Alzheimer's therapies.
Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. ChemotherapyIvone...
